Drug firm Ind-Swift Laboratories is targeting to garner revenues of Rs 1,500 crore by 2015. For achieving the same, the company will continue to focus on its active pharmaceuticals Ingredients (API) business in European Union, Japan, Australia and US which will be the main drivers of growth for future. At present, the company’s revenues stand at over Rs 1,000 crore.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API). The company’s business model is focused on domestic market and high-value mature regulated markets along with considerable focus on the emerging markets as well.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1517.90 |
Dr. Reddys Lab | 6362.00 |
Cipla | 1478.90 |
Zydus Lifesciences | 1066.95 |
Lupin | 1614.95 |
View more.. |